Christian Hoyer Millar, Director and
co-founder at Oxford Biodynamics provides an introduction to the company and updates
on recent events.
Click here to register
Bio: Christian read PPE at Lincoln College, Oxford.
His career started in consulting before moving Hoogovens/Hoechst as a director
of two of their subsidiaries in the UK, winning the Queen’s award for Exports
in one of those subsidiaries. He then worked in both investment banking and
venture capital, initially with Ensign Trust Plc.
Christian founded Oxford BioDynamics in 2007 with Dr.
Alexandre Akoulitchev and Dr. Aroul Ramadass. Christian was the Chairman
of both Chronos Therapeutics Limited and Sibelius Limited until August 2016, at
which point he stepped down from both roles although remains as a non-executive
director.
Company Description:
Oxford BioDynamics Plc is a biotechnology company focused on the
discovery and development of epigenetic biomarkers for use within the
pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary
technology platform, EpiSwitch™, aims to accelerate the drug
discovery and development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance of
personalised medicine.
In particular, EpiSwitch™ can
reduce time to market, failure rates and the costs at every stage of drug
discovery. Additionally, the technology provides significant insights
into disease mechanisms for drug discovery and product re‐positioning
programmes, and enables the personalisation of therapeutics for patients in the
context of challenging pricing environments where improved clinical outcomes
are critical.